Zydus Lifesciences Launches Biosimilar Denosumab for Cancer Patients
Filing Summary
Zydus Lifesciences Ltd. has launched a biosimilar product, Denosumab 120 mg SC, branded as ‘Zyrifa’, on December 10, 2025. This product is designed to manage bone health in cancer patients by reducing and delaying skeletal-related events. The biosimilar is priced at Rs 12,495 and targets patients with bone metastases from various cancers, including breast, prostate, lung, and others. The launch is part of Zydus’s broader strategy to expand its biosimilar offerings in oncology, enhancing access to critical care medications.
On December 10, 2025, Zydus Lifesciences Ltd. announced the launch of its biosimilar product, Denosumab 120 mg SC, under the brand name ‘Zyrifa’. This product is intended for the treatment of bone health issues in cancer patients, specifically targeting the reduction and delay of Skeletal Related Events (SREs) in individuals with solid tumors and multiple myeloma.
The biosimilar is priced at a Maximum Retail Price (MRP) of Rs 12,495. It is designed to provide treatment for patients experiencing bone metastases due to cancers such as breast, prostate, lung, myeloma, kidney, thyroid, head and neck, among others. Bone metastases occur when cancer spreads to the bones, indicating an advanced stage of the disease.
Bone metastases are a significant complication in cancer, affecting patient quality of life through pain, fractures, spinal cord compression, and reduced mobility. The condition predominantly impacts the axial skeleton, including the spine, pelvis, and ribs, leading to severe complications.
Population studies indicate high rates of bone involvement in advanced cancer cases. In advanced breast or prostate cancer, bone involvement affects 50-70% of patients, while 15-40% of lung, kidney, thyroid, and melanoma cases develop skeletal metastases over time.
Zydus Lifesciences Ltd. has been expanding its biosimilar portfolio to address various cancers, including breast and prostate cancer, as well as other solid tumors and blood cancers. The company has also formed partnerships with diagnostic companies to enhance its offerings.
Zydus Lifesciences Ltd. is a diversified life-sciences company focusing on pharmaceuticals and consumer wellness. It employs 27,000 people globally, including 1,500 scientists in R&D, and is committed to providing quality healthcare solutions. For more information, visit www.zyduslife.com.